94 related articles for article (PubMed ID: 15160950)
1. Comparison of bone marrow aspirates and biopsies in pediatric patients with ALL at days 7 and 14 of induction therapy.
Countouriotis A; Landaw EM; Naeim F; Moore TB; Sakamoto KM
Leuk Lymphoma; 2004 Apr; 45(4):745-7. PubMed ID: 15160950
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the cellularity and presence of residual leukemia in bone marrow aspirate and biopsy specimens in pediatric patients with acute lymphoblastic leukemia (ALL) at day 7-14 of chemotherapy.
Kidd PG; Saminathan T; Drachtman RA; Ettinger LJ
Med Pediatr Oncol; 1997 Dec; 29(6):541-3. PubMed ID: 9324341
[TBL] [Abstract][Full Text] [Related]
3. Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia.
Zuna J; Moericke A; Arens M; Koehler R; Panzer-Grümayer R; Bartram CR; Fischer S; Fronkova E; Zaliova M; Schrauder A; Stanulla M; Zimmermann M; Trka J; Stary J; Attarbaschi A; Mann G; Schrappe M; Cario G
Br J Haematol; 2016 Jun; 173(5):742-8. PubMed ID: 26913693
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
[TBL] [Abstract][Full Text] [Related]
6. Comparison of multidimensional flow cytometry with standard morphology for evaluation of early marrow response in pediatric acute lymphoblastic leukemia.
Meshinchi S; Thomson B; Finn LS; Leisenring W; Green C; Radich JP; Loken M; Hawkins D
J Pediatr Hematol Oncol; 2001 Dec; 23(9):585-90. PubMed ID: 11902302
[TBL] [Abstract][Full Text] [Related]
7. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia.
Sandlund JT; Harrison PL; Rivera G; Behm FG; Head D; Boyett J; Rubnitz JE; Gajjar A; Raimondi S; Ribeiro R; Hudson M; Relling M; Evans W; Pui CH
Blood; 2002 Jul; 100(1):43-7. PubMed ID: 12070006
[TBL] [Abstract][Full Text] [Related]
8. Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia.
Schultz KR; Massing B; Spinelli JJ; Gaynon PS; Wadsworth L
Med Pediatr Oncol; 1997 Jul; 29(1):16-22. PubMed ID: 9142200
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow leukemic progenitor cell content in pediatric T-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse.
Uckun FM; Gaynon PS; Stram DO; Sensel MG; Sarquis MB; Willoughby M
Leuk Lymphoma; 2001 Jan; 40(3-4):279-85. PubMed ID: 11426549
[TBL] [Abstract][Full Text] [Related]
11. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.
Coustan-Smith E; Behm FG; Sanchez J; Boyett JM; Hancock ML; Raimondi SC; Rubnitz JE; Rivera GK; Sandlund JT; Pui CH; Campana D
Lancet; 1998 Feb; 351(9102):550-4. PubMed ID: 9492773
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of persistent peripheral blood and bone marrow lymphoblasts on day 15 of therapy in childhood acute lymphoblastic leukemia as detected by flow cytometry.
Jaworska-Posadzy A; Styczynski J; Kubicka M; Debski R; Rafinska-Kurylo B; Kolodziej B; Pogorzala M; Wysocki M
Anticancer Res; 2011 Apr; 31(4):1453-7. PubMed ID: 21508402
[TBL] [Abstract][Full Text] [Related]
13. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome.
Norén-Nyström U; Roos G; Bergh A; Botling J; Lönnerholm G; Porwit A; Heyman M; Forestier E
Leukemia; 2008 Mar; 22(3):504-10. PubMed ID: 18094715
[TBL] [Abstract][Full Text] [Related]
15. Clinical importance of speed of response to therapy in childhood lymphoblastic leukaemia.
Lilleyman JS
Leuk Lymphoma; 1998 Nov; 31(5-6):501-6. PubMed ID: 9922040
[TBL] [Abstract][Full Text] [Related]
16. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
17. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
18. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
[TBL] [Abstract][Full Text] [Related]
19. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
